Premium
Breakthrough invasive fungal infections: Who is at risk?
Author(s) -
Jenks Jeffrey D.,
Cornely Oliver A.,
Chen Sharon C.A.,
Thompson George R.,
Hoenigl Martin
Publication year - 2020
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.13148
Subject(s) - intensive care medicine , epidemiology , antifungal , medicine , intensive care unit , population , invasive candidiasis , environmental health , dermatology , fluconazole
The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop breakthrough IFIs with substantial morbidity and mortality in this population. Here, we review the most significant risk factors for breakthrough IFIs in haematology patients, solid organ transplant recipients, and patients in the intensive care unit, focusing particularly on host factors, and highlight areas that require future investigation.